All News

Andrew Evens, DO & Joanna Rhodes, MD, on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across NJ.

Experts discussed proactive strategies for managing diarrhea and making dose reduction decisions with NALIRIFOX in pancreatic cancer.

Patients in US counties with the highest medical debt burden had higher odds of stage IV cancer diagnosis and worse survival than those in the lowest-burden counties.

Two teams of multiple myeloma experts debate the use of early CAR T-cell therapies and bispecific antibodies based on key trial data and various hot topics.

Experts highlight how AI-based tools can assist with digital pathology, documentation, medical imaging, and other relevant areas in genitourinary oncology.

The FDA cited outstanding manufacturing observations while raising no concerns about clinical data, bioequivalence, or stability in its CRL.

A retrospective series found a 75% response rate adding lenvatinib after pembrolizumab progression in dMMR endometrial cancer, said Susana Campos, MD, MPH.

Bispecific antibodies “will form the standard backbone agents for multiple myeloma therapies,” according to Hans Lee, MD.

Experts discussed how NALIRIFOX compares with FOLFIRINOX and gemcitabine/nab-paclitaxel as frontline therapy for metastatic pancreatic cancer.

The FDA granted fast track designation to safusidenib for IDH1-mutant glioma, building on updated phase 2 data and a broadening clinical development program.

Phase 3 LITESPARK-011 results show belzutifan/lenvatinib significantly improved PFS and ORR vs cabozantinib in previously treated advanced ccRCC.

Experts gathered to discuss various facets of early-relapse multiple myeloma treatment, such as exposure vs refractoriness and CAR T vs bispecifics.

Barbara Burtness, MD, outlined the rationale behind OrigAMI-4 eligibility criteria and how tumor boards can select patients with HNSCC for amivantamab.

A nurse practitioner, clinical social worker, and patient discuss navigating treatment-related concerns and psychosocial considerations in multiple myeloma.

[68Ga] Ga-NYM096 is the first China-originated radiopharmaceutical to receive FDA breakthrough therapy designation for ccRCC.

In a phase 2 trial, pembrolizumab/denosumab produced a 31% objective response rate in patients with pretreated advanced clear cell renal cell carcinoma.

Results from the INTERpath-001 trial of V0940 plus pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in resected melanoma.

Treatment until progression may not be the way forward with bispecific antibodies, according to Hans Lee, MD.

Barbara Burtness, MD, discussed strategies for managing skin reactions and MET-driven edema in head and neck cancer treated with subcutaneous amivantamab.

Laura Alder, MD, discussed a retrospective analysis evaluating tarlatamab’s efficacy and safety in patients with SCLC and brain metastases excluded from DeLLphi-304.

Men with disabilities were less likely to have received prior PSA testing than men without disabilities, with mobility disability showing the most consistent association.

Laura Alder, MD, discussed how her team at Duke monitors and educates patients for immune-related toxicities while receiving tarlatamab for brain metastases.

Detailed findings from the phase 3 DESTINY-Lung04 trial will be presented at a future medical meeting and shared with regulatory health authorities.

Hans Lee, MD, said it is only a matter of time before bispecific antibodies move into the newly diagnosed multiple myeloma setting.

The FDA has cleared an investigational new drug application for C-CAR039, a CD19/CD20 bispecific CAR T-cell therapy, in relapsed/refractory large B-cell lymphoma.

In a retrospective cohort study, neoadjuvant chemoimmunotherapy produced a deep pathologic response in 67.0% of patients with resectable HNSCC.

The FDA has granted OncoSil Medical a humanitarian device exemption for its intratumoral radiation device in unresectable, non-metastatic distal cholangiocarcinoma.

The phase 3 eVOLVE-Lung02 trial will halt after an independent committee concluded that volrustomig plus chemotherapy was unlikely to improve survival.

Experts emphasize that ongoing communication, whether from an academic or community oncology standpoint, is key for providing optimal multiple myeloma care.

Laura Alder, MD, discussed how tarlatamab’s intracranial activity compared with chemotherapy and radiation options for brain metastases in small cell lung cancer.